Monoclonal Antibody Treatment Can Help Prevent Hospitalizations Due to COVID-19

If you recently tested positive for COVID-19, you may qualify for an exciting new therapy called monoclonal antibody treatment. Although it is not a cure, the use of monoclonal antibodies may lessen COVID-19 symptom severity and help keep high-risk patients out of the hospital.

Monoclonal antibodies are actually laboratory-made proteins that mimic natural antibodies’ ability to fight viruses such as COVID-19. Clinical trials have shown fewer COVID-19-related hospitalizations or emergency room visits and a decrease in the amount of virus in an infected person’s blood in patients at high risk for developing severe COVID-19 symptoms.

Monoclonal Antibody.png

Currently, monoclonal antibody treatment may only be used in adults and adolescents (12-17 years old) with mild to moderate COVID-19 symptoms who:

  • Recently had a positive COVID-19 test
  • Are within 10 days of first experiencing symptoms
  • Do not need to be hospitalized for COVID-19 treatment
  • Weigh at least 88 pounds
  • Are in one of the following high-risk categories:
    • Are age 65 and older or have chronic kidney disease, BMI of 35 or greater, diabetes, or an immunosuppressive disease
    • Are age 55 to 64 AND have cardiovascular disease, hypertension, chronic respiratory diseases, or COPD
    • For adolescents: high BMI, sickle cell disease, heart disease, neurodevelopmental disorders, a medical-related technological dependence, asthma or other chronic respiratory disease

Talk to your healthcare provider as soon as you test positive to see if you may be eligible to receive monoclonal antibody treatment. For the treatment to work, it must be given within 10 days of first experiencing mild to moderate COVID-19 symptoms.

For more information on monoclonal antibody treatment for COVID-19, click here.​​​​